NDC product
ENTECAVIR
NDC 16714-717 · NorthStar RxLLC
Key facts
| Product NDC | 16714-717 |
|---|---|
| Proprietary name | ENTECAVIR |
| Nonproprietary name | ENTECAVIR |
| Substances | ENTECAVIR |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | NorthStar RxLLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA206872 |
| Pharmacologic classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Analog [EXT], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| Marketing start | Jun 15, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: